Browsing by Author "Vulule, John M"
Now showing items 1-3 of 3
-
Interleukin (IL)-13 promoter polymorphisms (-7402 T/G and -4729G/A) condition susceptibility to pediatric severe malarial anemia but not circulating IL-13 levels
Okeyo, Winnie A; Munde, Elly O; Okumu, Wilson; Raballah, Evans; Anyona, Samuel B; Vulule, John M; Ong’echa, John M; Perkins, Douglas J; Ouma, Collins (BMC Immunology, 2013-03-25)In holoendemic Plasmodium falciparum transmission areas such as western Kenya, severe malarial anemia [SMA, hemoglobin (Hb) < 6.0 g/dL, with any density parasitemia] is the most common clinical manifestation of severe ... -
Interleukin (IL)-13 promoter polymorphisms (-7402 T/G and -4729G/A) condition susceptibility to pediatric severe malarial anemia but not circulating IL-13 levels
Okeyo, Winnie A; Munde, Elly O; Okumu, Wilson; Raballah, Evans; Anyona, Samuel B; Vulule, John M; Ong’echa, John M; Perkins, Douglas J; Ouma, Collins (BMC Imunology, 2013-03-25)n holoendemic Plasmodium falciparum transmission areas such as western Kenya, severe malarial anemia [SMA, hemoglobin (Hb) < 6.0 g/dL, with any density parasitemia] is the most common clinical manifestation of severe malaria ... -
Interleukin (IL)-13 promoter polymorphisms (-7402 T/G and -4729G/A) condition susceptibility to pediatric severe malarial anemia but not circulating IL-13 levels.
Okeyo, Winnie A; Munde, Elly O; Okumu, Wilson; Raballah, Evans; Anyona, Samuel B; Vulule, John M; Ong’echa, John M; Perkins, Douglas J; Ouma, Collins (BMC Immunology, 2013-03-13)In holoendemic Plasmodium falciparum transmission areas such as western Kenya, severe malarial anemia [SMA, hemoglobin (Hb) < 6.0 g/dL, with any density parasitemia] is the most common clinical manifestation of severe ...